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19th CardioVascular Summit: TCTAP 2014immediately after intervention for ISR. We evaluated yellow color grade (grade 0-3),
neointima coverage grade (grade 0-2), and thrombus (presence or absence) at the
culprit lesion. The patients were divided into two groups according to the maximum
yellow color grade of the lesion (White: grade 0 or 1 vs. Yellow: grade 2 or 3) and
their ISR recurrence was examined by angiography at one-year follow-up. Diameter
stenosis >50% was deﬁned as ISR.
Results: The incidence of ISR recurrencewas higher in the patientswith yellow ISR lesion
than in those with white ISR lesion (67.8% vs. 10.0%, p¼0.018). Thrombus was not
detected in both groups. Neointima coverage grade was not different between the groups.
Conclusion: The patients with yellow ISR lesion had the higher incidence of ISR
recurrence than those with white ISR lesion.
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The Impact of Angiographic Peri-contrast Staining After Second the Impact of
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Implantationeneration DES Implantation
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Norihiro Kobayashi, Yasunari Sakamoto, Hideyuki Takimura, Shinsuke Mori,
Hiroya Takafuji, Makino Kenji
Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan
Background: Several studies showed peri-contrast staining (PSS) was be associated
with TLR and very late stent thrombosis. However, the incidence and clinical sequela
of PSS after second generation DES implantation are unclear, so we retrospectively
evaluate the clinical outcomes.
Methods: This study consisted of de novo 1622 lesions in 1150 patients that were
treated with second generation DES (ZES, EES, and BES) in a single center. They
were evaluated by follow-up angiography within 12 months after stent implantation,
from April 2009 to August 2012. We divided into PSS group and non-PSS group and
compared the two groups in clinical and angiographical outcomes.
Results: There were no signiﬁcant differences between the two groups in patient back-
ground and lesion characteristics. Late acquired PSS was observed in 12 lesions (0.74%)
in 11 patients (0.96%). In these lesions, 2 lesions (0.63%) were observed in BES, 4 lesions
(0.4%) were EES and 6 lesions (1.9%) were ZES. (N.S.) Stent fracture was more
frequently observed in lesions with PSS than in lesions without PSS (29.4% versus 1.1%,
P <0.0001). Cumulative incidence of TLR and MACE in the PSS group was higher than
that in the non-PSS group ( 33.3% versus 5.5%, and 41.7% versus 9.6%, P <0.05).
Conclusion: In this study, PSS after second generation DES seemed to be associated
with TLR and MACE.
TCTAP A-068
The Timing of Occurrence of Stent Fracture After Sirolimus-eluting Stent
Implantation
Tomoyuki Fukuzawa, Takahiro Watanabe, Yuichi Hanaki, Seigen I, Hajime Aoki,
Kenichi Kato
Yokohama Rousai Hospital, Yokohama, Japan
Background: SF was more commonly reported in sirolimus-eluting stent (SES), right
coronary artery (RCA), longer duration of implant and longer stent length. However
the timing of stent fracture of each coronary is unknown. The purpose of this study is
to assess the time point at which SF of each coronary occurs by the multidetector
computed tomography (MDCT).
Methods: We performed 64-slice MDCT on asymptomatic and event-free 114 pa-
tients (156 lesions) who received SES implantation. These lesions are all RCA and left
anterior descending artery (LAD) to compare two coronary arteries. We investigated
the rate of SF, in-stent restenosis (ISR) and peri-stent aneurysms caused by SF. MDCT
deﬁnition of SF is complete separation or partial separation of stent struts. The average
ﬁrst CT follow-up period was 24.6months (5-75months). Then we conducted the
second MDCT 42.8 months (12-71 months) later after the ﬁrst MDCT to non-SF 45
patients (48 lesions).
Results: SF was identiﬁed in 32 lesions of 156 lesions (20.5%) at the ﬁrst MDCT. In
RCA, 14 stent fractures of 39 lesions were observed. Fracture rate was 35.8%. In
LAD, 18 stent fractures of 117 lesions were observed. Fracture rate was 15.3%. SF
was more observed in RCA than LAD at the ﬁrst MDCT (P¼0.006). ISR induced by
SF was 1 lesion (3.1%), peri-stent aneurysms were 2 lesions (6.2%). At the second
MDCT, new SF occurred in 3 lesions of non-SF 48 lesions. The rate of new SF was
6.2%. The coronary of new SF was all LAD and new SF didn’t occur at RCA. About
these 3 lesions, ISR and peri-stent aneurysm induced by SF were not detected.
Conclusion: SF was more observed in RCA than LAD at the ﬁrst MDCT, however the
newSFwas identiﬁed in onlyLAD.AboutLAD, it is possibility to increase the rate ofSF in
chronic phase. We continue to follow up the patients who received SES implantation.S20 JACC Vol 63/12/Suppl STCTAP A-069
Clinical and Angiographic Results in Patients with Very Small Coronary Vessel
After Biolimus A9-eluting Stents Implantation
Soichiro Enomoto, Takenori Domei, Shoichi Kuramitsu, Yoshio Kazuno,
Makoto Hyodo, Toru Mazaki, Shinichi Shirai, Kenji Ando
Kokura Memorial Hospital, Kitakyushu, Japan
Background: Percutaneous coronary interventions (PCI) to small-diameter vessels
remain an important challenge because of increased complications.
Methods: Between May 2011 and January 2012, 83 patients with very small coronary
vessels (reference vessel diameter <2.5 mm) were submitted to PCI. Biolimus-eluting
stent (BES) was deployed at a low pressure with long inﬂation time.
Results: Two cases of distal edge dissection were observed and one of them needed
additional stent implantation. Postprocedural TIMI grade 3 ﬂows were achieved in all
patients. There were no death, myocardial infarction (MI) and target lesion revascular-
ization (TLR) during the initial hospitalization. The angiographic data is shown in
Figure. Average luminal diameters(ALD) in distal segments signiﬁcantly increased from
baseline (1.360.49 mm vs. 1.560.31, p<0.01). At 12 months after procedure, the rate
of TLR was 8.0%. There were no cardiac death and MI related to target lesions. Distal
ALD tended to increase from initial procedure (1.710.30mm, p¼0.07).
Conclusion: BES implantation to very small coronary vessels achieved a high clinical
success and luminal diameter distal to stent signiﬁcantly increased and remained
unchanged at 12-month follow-up.TCTAP A-070
One year Clinical, Angiographic, and Optical Coherence Tomography Outcomes
of 2nd Generation Drug Eluting Stents 6 Months Dual Antiplatelet Therapy
Between Biodegradable and Durable Polymer Stent
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Hyuck Moon Kwon1, Byeong Keuk Kim2, Myeong-Ki Hong2, Yangsoo Jang2
1Gangnam Severance Hospital, Seoul, Korea (Republic of), 2Yonsei University
Cardiovascular Hospital, Seoul, Korea (Republic of)
Background: Stent thrombosis has been strongly associated with discontinuation of
dual antiplatelet therapy. The central point of stent thrombosis seems to be the
impaired, or delayed re-endothelialization, and the most important histological and
morphometric predictors of late stent thrombosis (LST) were endothelial coverage and
the ratio of uncovered to total stent struts after drug-eluting stent (DES) implantation.
However, recent controversies regarding the risk of stent thrombosis in patients receiving
DES has brought up the issue of the appropriate duration of antiplatelet therapy after
percutaneous coronary intervention, and a recent study reported that the use of extended
DAPT for a period longer than 12 months in patients who had received DES was not
signiﬁcantly more effective than aspirin monotherapy in reducing the rate of MI or death
for cardiac causes. While second generation DES promote more favorable vascular
healing comparing to ﬁrst generation DES, biodegradable polymer containing stents
might have a yield in terms of duration of dual antiplatelet therapy (DAPT) than durable
polymer stents. We aimed to test whether biolimus-eluting stent (BES) with 6-month
DAPT would be non-inferior 12-month clinical and angiographic outcome to Zotar-
olimus-eluting stent (ZES) with 6-month DAPT.
Methods: This is a prospective, randomized, open-label, multicenter trial to compare
clinical events and angiographic data between BES and ZES stents. Currently, 621
patients were randomly assigned. The primary end point was a major adverse cardiac
events (MACE) at 12 months. Optical coherence tomography (OCT) at 6 month was
performed in 30 patients of each group. The primary endpoint was MACE, secondary
end points are target lesion failure, in-segment late loss (LL) at 12 months, and
neointimal hyperplasia (NIH) and uncovered stent strut (%) by OCT at 6month.
Results: Currently, clinical follow-up was available in 325 patients and angiographic
follow-up in 311 patients. The primary endpoints were not statistically differentj April 22–25, 2014 j TCTAP Abstracts/ORAL/Drug-eluting Stents
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19th CardioVascular Summit: TCTAP 2014between the BES and ZES, including MACE (5.5 vs. 6.4%; p ¼0.76) and stent
thrombosis (0.3 vs. 0.3%; p ¼ 0.99). The secondary endpoints also were not signif-
icantly different between BES and ZES, including target lesion failure (2.0 vs. 1.6%; p
¼ 0.53), in-segment LL (mm) at 12 months (0.090.37 vs. 0.050.39, p ¼0.61).
OCT at 6 month revealed that mean NIH thickness (mm) of BES and ZES were
59.130.3, 54.025.6, respectively (p¼0.49), and uncovered stent strut percentage
(%) of BES and ZES were 20.521.8, 17.722.4, respectively (p¼0.63).
Conclusion: BES with biodegradable polymer with 6 month DAPT did not increase
the risk of MACE, stent thrombosis, target lesion failure, and LL at 12 months
comparing with ZES with durable polymer. The 2nd generation DES including BES
and ZES are comparably efﬁcacious. Our results need to be conﬁrmed in larger trials,
and further follow up data.
TCTAP A-071
One-year Outcomes Following Implantation of the Resolute Zotarolimus-eluting
Stent in an Asian, Dual Vessel Population: RESOLUTE Asia
Robaayah Zambahari1, Michael Lee2, Shirish Hiremath3
1National Heart Institute, Kuala Lumpur, Malaysia, 2Queen Elizabeth Hospital,
Kowloon, Hong Kong, China, 3Ruby Hall Clinic, Pune, India
Background: Coronary artery disease in Asian populations is rising and is
commonly treated with drug-eluting stents (DES). Clinical evidence is needed on
outcomes of new-generation DES implantation in Asian patients with lesions in more
than 1 vessel.
Methods: Patients with de novo lesions (length 27 mm and reference vessel
diameter 2.25-4.0 mm) in 2 vessels were enrolled from 24 sites across Asia. The
Resolute(R) zotarolimus-eluting stent (R-ZES) was implanted in both lesions at the
same index procedure. Postprocedure dual antiplatelet therapy (DAPT) was recom-
mended for 6 to 12 months. An independent clinical events committee adjudicated all
events. The primary endpoint was 1-year target vessel failure (TVF; cardiac death,
target vessel myocardial infarction [TVMI], or clinically-driven target vessel revas-
cularization [TVR]). A secondary endpoint was target lesion failure (TLF; cardiac
death, TVMI, or clinically-driven target lesion revascularization [TLR]).
Results: There were 202 subjects (n¼406 lesions) enrolled. The mean age was 60.1
years (standard deviation [SD], 9.8), 85% (n¼171) of patients were male, and 46%
(n¼93) had diabetes. DAPT use was 92% (n¼185/201) at 6 months and 91% (n¼182/
201) at 1 year. Mean lesion length was 15.3 mm (SD, 6.6) and 61.1% were ACC/AHA
class B2/C. The rate of TVF at 1 year was 4.5% (n¼9/202); the rate of TLF was 4.0%
(n¼8/202). Cardiac death occurred in 0.5% (n¼1) of patients, TVMI in 2.5% (n¼5),
clinically-driven TVR in 1.5% (n¼3), and clinically-driven TLR in 1.5% (n¼3). There
were no events of Academic Research Consortium deﬁnite or probable stent
thrombosis.
Conclusion: Use of the R-ZES was safe and effective with a low rate of clinical
events and no stent thrombosis events in Asian patients with dual-vessel coronary
artery disease.
TCTAP A-072
The Outcome of Drug-eluting Stent Implantation in Saphenous Vein Graft
Comparing Among Recipient Native Vessel Territories
Tahei Ichinohe, Kazushige Kadota, Shunsuke Kubo, Koshi Miyake, Yusuke Hyodo,
Seiji Habara, Tanaka Hiroyuki, Takeshi Tada, Yasushi Huku, Tsuyoshi Goto,
Kazuaki Mistudo
Kurashiki Central Hospital, Okayama-ken Kurashiki-shi, Japan
Background: The efﬁcacy of drug eluting stent for saphenous vein graft (SVG) is
proven, however the difference of the location of the recipient artery remains unclear.
In this study, we compared angiographic outcome for SVG, including in-stent reste-
nosis (ISR), stent fracture (SF) or target lesion revascularization (TLR) among
recipient native vessel territory (left circumﬂex artery group versus left ascending and
right coronary artery group).
Methods: From February 2004 to January 2013, 45 patients with 68 lesions under-
went drug-eluting stent implantation in SVG. Angiographic follow-up at 3-6 months
was obtained in 45 lesions (follow-up rate; 66%).
Results: Data are shown in the table.
Conclusion: Recurrence of ISR is frequent in the LCX group after DES implantation
for SVG lesions. The location of recipient artery should be taken into account in case
of treatment of SVG lesions after DES implantation.JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP Abstracts/ORATCTAP A-073
Angiographic and Clinical Outcome of Drug-eluting Stent Implantation for Right
Coronary Ostial Lesion
Shinsuke Mori, Toshiya Muramatsu, Reiko Tsukahara, Yoshiaki Ito, Hiroshi Ishimori,
Keisuke Hirano, Masatsugu Nakano, Masahiro Yamawaki, Motoharu Araki,
Tamon Kato, Norihiro Kobayashi, Hideyuki Takimura, Yasunari Sakamoto,
Masakazu Tsutsumi, Hiroya Takafuji, Takahiro Tokuda, Makino Kenji
Saiseikai Yokohama-City Eastern Hospital, Yokohama, Japan
Background: In spite of availability of drug-eluting stent (DES), clinical outcome of
percutaneous coronary intervention for right coronary ostial lesion (RCAos) is still
poor. So we investigated the angiographic and clinical outcome of DES implantation
for True RCAos.
Methods: This was a single center non-randomized retrospective study. From April
2007 to July 2012, 67 consecutive patients who underwent DES implantation for
de novo RCAos were included. RCAos was deﬁned as the lesion being within
3 mm of the ostium. We deﬁned True RCAos as lesion contained just RCA ostium.
Subjects were classiﬁed into two groups: the patients treated for True RCAos (True
group, 35 patients) and for Not true RCAos (Not true group, 32 patients). Endpoint
was binary restenosis at 10 months and target lesion revascularization (TLR) at
12 months.
Results: True group was older than Not true group. There were no signiﬁcant dif-
ferences between two groups in gender, hypertension, hyperlipidemia, diabetes, and
hemodialysis. Despite True group had shorter stent length and larger lesion diameter,
they had a higher rate of binary restenosis at 10 months (35.5% vs. 10.0%, p<0.05)
and TLR at 12 months (28.6% vs. 6.3%, p<0.05) than Not true group.
Conclusion: Our data indicates that the outcome of DES implantation for True
RCAos is worse than that of DES implantation for Not true RCAos.
TCTAP A-074
Five-year Clinical Outcomes of Drug Eluting Stents According to the On-label
and Off-label Usage
Jeong-Hwan Cho, Chan-Hee Lee, Hyun-Wook Lee, Tae-Hun Kwon, Yoon-Jung Choi,
Jang-Won Son, Sang-Hee Lee, Ung Kim, Jeon-Seon Park, Dong-Gu Shin,
Young-Jo Kim
Yeungnam University Hospital, Daegu, Korea (Republic of)
Background: The purpose of this study was to evaluate clinical outcomes of drug-
eluting stent (DES) according to on versus off-label indication for 5 years.
Methods: A total of 929 consecutive patients who performed percutaneous coronary
intervention (PCI) with DES from April 2005 to December 2007 were enrolled. Those
patients were divided into two groups according to on (n¼449) versus off-label
(n¼480) indication. Off label usage of DES was indicated in patients with long ste-
notic lesion (>30mm), total occlusion, bifurcation, ostial lesion, left main disease,
multivessel disease, saphenous vein graft and thrombus present. Clinical outcomes of
major adverse cardiac event (MACE) including death, target vessel revascularization
(TVR), target lesion revascularization (TLR), myocardial infarction (MI) and stent
thrombosis (ST) were compared between two groups for 5 years. Risk factors for
MACE according to on versus off label indication.
Results: There were no difference between two groups in baseline characteristics,
except diabetes (24.9% [Group 1] vs. 35.4%[Group 2], p¼0.002). Of 929 patients
enrolled in this study, seven hundred ten patients were completely monitored for
5years (follow up rate 76.4%). At one year, group 2 was associated of higher inci-
dence of MACE (1.9% vs. 7.5%, p¼0.000), because of TLR(1.4% vs. 3.4%,
p¼0.047), TVR(1.6% vs. 5.2%, p¼0.004) and stent thrombosis(0.2% vs. 1.5%,
p¼0.042). From 1 year until 5 year clinical follow up, group 2 also had a higher
incidence of MACE(6.4% vs. 11.3%, p¼0.014) because of TLR(3.7% vs. 7.1%,
p¼0.029). The rate of total MACE were higher in off-label usage than those of
on-label (9.1% vs. 20.0%, p¼0.000). Multivessel disease [HR 2.0, p¼0.004] and
diabetes [HR 1.7 p¼0.017] were independent risk factors for MACE in multivariate
analysis.
Conclusion: Patients with On-label indication of DES had better long-term clinical
outcomes than those with off-label. Further large clinical trials will be warranted.L/Drug-eluting Stents S21
